Clinical trial · Observational
Liquid Biopsy-based Monitoring System for Relapse of HCC After Liver Transplantation: A Multi-center and Prospective Study
Liquid Biopsy-based Monitoring System for Relapse of Hepatocellular Carcinoma Associated With Hepatitis B After Liver Transplantation: A Multi-center and Prospective Study
NCT03708705CI-TRIAL-00035375unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to develop a novel, reliable, liquid biopsy-based biomarker system for relapse of HCC associated with hepatitis B after liver transplantation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Risk model of tumor relapse | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Relapse
- description
- Relapse of tumor within two years after liver transplantation
- interventionNames
- Other: Risk model of tumor relapse
- label
- Non-relapse
- description
- Non-relapse of tumor within two years after liver transplantation
- interventionNames
- Other: Risk model of tumor relapse
Primary outcomes (1)
- measure
- relapse rate of tumor
- timeFrame
- two years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: transplants for HCC Exclusion Criteria: Liver transplantation due to other disease
References
Publications (0)
Data not yet available
No reference posted for this study.